STOCK TITAN

Athira Pharma, Inc. - ATHA STOCK NEWS

Welcome to our dedicated page for Athira Pharma news (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma stock.

About Athira Pharma, Inc.

Athira Pharma, Inc. (NASDAQ: ATHA), headquartered in Bothell, Washington, is a clinical-stage biopharmaceutical company dedicated to advancing innovative therapies for neurodegenerative diseases. Leveraging its proprietary platform targeting the neurotrophic hepatocyte growth factor (HGF) system, Athira aims to restore neuronal health, mitigate neurodegeneration, and alter disease progression. By focusing on disease-modifying approaches, the company seeks to address the underlying mechanisms of conditions such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).

Therapeutic Focus and Pipeline

Athira's therapeutic pipeline is built around small-molecule drug candidates that modulate the HGF system to activate neuroprotective, neurotrophic, and anti-inflammatory pathways. Key programs include:

  • ATH-1105: A next-generation, orally administered small molecule designed to treat ALS and other neurodegenerative diseases. Preclinical studies have demonstrated its ability to reduce neurofilament light chain (NfL) levels, a biomarker for neurodegeneration, while improving motor function and neuronal survival.
  • Fosgonimeton (ATH-1017): A subcutaneously administered drug candidate targeting mild-to-moderate Alzheimer's disease. Despite mixed results in clinical trials, it showed promising biomarker improvements, suggesting potential neuroprotective effects.

Scientific Innovation

Athira's unique approach centers on the HGF system, an endogenous repair mechanism critical for neuronal health. By enhancing this pathway, the company targets the root causes of neurodegeneration, such as mitochondrial dysfunction, protein aggregation, and inflammation. This differentiates Athira from competitors focusing primarily on symptomatic relief.

Market Position and Challenges

Operating in the highly competitive biopharmaceutical industry, Athira faces challenges such as regulatory hurdles, clinical trial risks, and competition from established players. However, its focus on a novel therapeutic pathway and its shift toward ALS with ATH-1105 position it as a potential leader in addressing unmet needs in neurodegenerative disease therapeutics.

Strategic Outlook

Following the mixed outcomes of its LIFT-AD trial for Alzheimer's, Athira has prioritized ATH-1105 for ALS, supported by robust preclinical data. The company is conducting a Phase 1 trial and plans to initiate ALS patient dosing in 2025. Additionally, Athira is exploring strategic alternatives, including partnerships, to extend its financial runway and advance its pipeline.

Through its innovative platform, focused pipeline, and commitment to addressing unmet medical needs, Athira Pharma is poised to make significant contributions to the treatment landscape for neurodegenerative diseases.

Rhea-AI Summary

Athira Pharma (ATHA) presented results from its ACT-AD trial for fosgonimeton, a treatment for mild-to-moderate Alzheimer's disease, at the AAIC 2022. While the primary endpoint was not statistically significant, secondary analyses showed numerical improvements in daily living activities and cognitive measures. Notably, a significant reduction in neurofilament light chain (NfL), a biomarker of neurodegeneration, was observed in a subgroup receiving fosgonimeton monotherapy. The positive tolerability profile and ongoing LIFT-AD study offer further exploration into its therapeutic potential.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
-
Rhea-AI Summary

Athira Pharma (ATHA) showcased preclinical data on its lead candidate, fosgonimeton (ATH-1017), at the AAIC 2022. The active metabolite, fosgo-AM, demonstrated neuroprotective effects in neuron cultures, enhancing neuron survival and neurite growth while mitigating neurotoxic impacts. Furthermore, novel orally bioavailable small molecules were shown to reverse memory deficits in animal models, promising for Alzheimer's treatment. These developments underline Athira's commitment to advancing its innovative therapies targeting neurodegenerative disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
-
Rhea-AI Summary

Athira Pharma (NASDAQ: ATHA) announced its participation in the Alzheimer’s Association International Conference (AAIC) 2022, taking place from July 31 to August 4, 2022. Chief Medical Officer Hans Moebius will present results from the ACT-AD Phase 2 proof-of-concept study on fosgonimeton (ATH-1017) targeting mild-to-moderate Alzheimer’s patients. The conference will include discussions on novel Alzheimer’s treatments, with Athira presenting data on its small molecule HGF/MET platform aimed at neuroprotection and cognitive improvement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
conferences clinical trial
Rhea-AI Summary

Athira Pharma (ATHA) announced topline results from its ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate Alzheimer’s disease. The primary endpoint of statistically significant change in ERP P300 latency was not met, suggesting diminished effect when combined with standard-of-care AChEIs. However, a subgroup analysis indicated improved ERP P300 latency and cognitive performance in patients on fosgonimeton monotherapy compared to placebo. Fosgonimeton demonstrated a favorable safety profile, and insights gained will inform the ongoing LIFT-AD study.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-66.27%
Tags
-
Rhea-AI Summary

Athira Pharma, Inc. (NASDAQ: ATHA) has established a Scientific Advisory Board (SAB) comprising leading experts in neurology and neurodegenerative diseases. The board, chaired by Athira's Chief Medical Officer, Dr. Hans Moebius, aims to provide strategic guidance for the development of Athira's novel small molecule compounds targeting conditions like Alzheimer’s and Parkinson’s disease. SAB members include prominent researchers from esteemed institutions, enhancing Athira’s capability in advancing its pipeline for neurological treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
management
-
Rhea-AI Summary

Athira Pharma (NASDAQ: ATHA) announced that its shareholders have approved the election of three new independent directors: Joseph Edelman, John M. Fluke, Jr., and Grant Pickering. CEO Mark Litton expressed gratitude for shareholder support, emphasizing the directors' contributions during a crucial phase for the company. Athira will continue to advance its clinical trials, focusing on its lead drug candidate, fosgonimeton (ATH-1017), aiming to enhance shareholder value. The final voting results will be disclosed in a Form 8-K filing with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
none
Rhea-AI Summary

Athira Pharma (NASDAQ: ATHA) has announced that its board recommends shareholders vote 'FOR' its three qualified director nominees on the WHITE proxy card. As Richard A. Kayne suspends his proxy contest, the board expresses gratitude for shareholder support and emphasizes its commitment to advancing Athira's strategy, especially with topline results from the Phase 2 ACT-AD study expected soon. The board believes it is well-equipped to drive company success, focusing on its developments in neurodegenerative diseases like Alzheimer’s and Parkinson’s.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.88%
Tags
none
-
Rhea-AI Summary

On May 16, 2022, Ric Kayne, a shareholder of Athira Pharma (NASDAQ: ATHA), announced the suspension of his campaign for board election amid concerns about the company's future leadership and strategy for ATH-1017. Despite expressing optimism about the drug's potential, Kayne acknowledged that a close vote could lead to a contentious board dynamic. He emphasized shareholder engagement, urging them to voice their opinions, while asserting the need for enhanced clinical management in light of upcoming trial results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
management
-
Rhea-AI Summary

Athira Pharma (NASDAQ: ATHA) announced promising preclinical findings for its small molecules, ATH-1018 and ATH-1019, targeting the HGF/MET signaling pathway. Presented at the 2022 Peripheral Nerve Society Annual Meeting, results showed significant improvement in pain-related behaviors in a diabetic neuropathy model. Notably, the effects persisted even after the compounds were cleared from plasma, suggesting long-lasting benefits. Athira aims to further evaluate these candidates to enhance its pipeline for treating diabetic neuropathy and other neurodegenerative conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
Rhea-AI Summary

Athira Pharma (NASDAQ: ATHA) reported its Q1 2022 financial results and discussed progress in clinical studies, including the ACT-AD Phase 2 Alzheimer's study set to release topline data by the end of Q2 2022. The company increased R&D expenses to $14.5 million, up from $7.4 million in Q1 2021, and general and administrative costs surged to $8.9 million due to headcount growth. The net loss also widened to $21.0 million, or $0.56 per share, compared to $8.9 million, or $0.25 per share, in the same period last year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.02%
Tags

FAQ

What is the current stock price of Athira Pharma (ATHA)?

The current stock price of Athira Pharma (ATHA) is $0.3502 as of March 6, 2025.

What is the market cap of Athira Pharma (ATHA)?

The market cap of Athira Pharma (ATHA) is approximately 14.8M.

What does Athira Pharma specialize in?

Athira Pharma specializes in developing small-molecule therapies targeting the neurotrophic HGF system to restore neuronal health and slow neurodegeneration.

What is the focus of Athira's drug pipeline?

Athira's pipeline focuses on disease-modifying treatments for neurodegenerative diseases like Alzheimer's disease, ALS, and Parkinson's disease.

What is ATH-1105?

ATH-1105 is an orally administered, next-generation small molecule in development for ALS and other neurodegenerative diseases. It has shown promising preclinical results.

What differentiates Athira Pharma from its competitors?

Athira's proprietary focus on the neurotrophic HGF system sets it apart, targeting the root causes of neurodegeneration rather than just alleviating symptoms.

What challenges does Athira Pharma face?

Athira faces challenges such as clinical trial risks, regulatory hurdles, competition, and financial sustainability as a clinical-stage company.

What was the outcome of the LIFT-AD trial?

The LIFT-AD trial for fosgonimeton in Alzheimer's disease did not meet its primary endpoint but showed promising biomarker improvements and subgroup benefits.

What is the significance of the HGF system in Athira's research?

The HGF system is a key repair mechanism for neuronal health, and Athira's therapies aim to enhance this pathway to counteract neurodegeneration.

What are Athira's future plans for ATH-1105?

Athira plans to complete Phase 1 trials for ATH-1105 in 2024 and begin dosing ALS patients in 2025, with a focus on advancing its clinical development.

How does Athira generate revenue?

As a clinical-stage company, Athira's revenue model may include future drug commercialization, licensing agreements, and strategic partnerships.

What strategic alternatives is Athira exploring?

Athira is considering partnerships and financing options to extend its cash runway and support the development of its pipeline, particularly ATH-1105.
Athira Pharma, Inc.

Nasdaq:ATHA

ATHA Rankings

ATHA Stock Data

14.80M
32.16M
1.95%
62.14%
4.05%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
BOTHELL